Randomized, double‐blind, phase 1a single‐ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers

• Main Authors: William K. Schmidt (Author), Irene Cortés‐Puch (Author), Cindy B. McReynolds (Author), Glenn E. Croston (Author), Sung Hee Hwang (Author), Jun Yang (Author), Theresa L. Pedersen (Author), Karen M. Wagner (Author), Theresa T. Pham (Author), Thomas Hunt (Author), Bruce D. Hammock (Author)
• Format: Book
• Published: Wiley, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Chronic pain represents a significant unmet medical need, affecting one‐fifth of the U.S. population. EC5026 is a small molecule inhibitor of the enzyme soluble epoxide hydrolase (sEH) which is being developed as a novel non‐opioid, non‐NSAID analgesic. EC5026 prolongs the action of epoxy f...